Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
复制标题
DOI：
10.1136/gutjnl-2019-319104
复制
发表时间：
2020-10-01
期刊：
影响因子：
24.5
通讯作者：
Loomba, Rohit
中科院分区：
文献类型：
--
作者：
Dufour, Jean-Francois;Caussy, Cyrielle;Loomba, Rohit
非酒精性脂肪性肝炎(NASH)正成为导致肝硬变的主要原因，NASH相关并发症的负担预计将在未来几年大幅增加。几种具有不同作用机制的分子目前正在开发中，用于治疗NASH，尽管到目前为止报道的疗效有限。鉴于NASH病理生理机制的复杂性，需要多个靶点和多个途径的参与才能提高药物干预的效果，这为NASH的综合治疗提供了理论基础。随着该领域向联合治疗方向发展，本文根据目前的治疗格局，回顾了这种联合治疗NASH的基本原理，以及这种方法的优点和局限性。
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.